Journal Article

Determination of antifungal drug susceptibilities of <i>Aspergillus</i> species by a fluorescence-based microplate assay

S. Arunmozhi Balajee, Alexander Imhof, Jennifer L. Gribskov and Kieren A. Marr

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 55, issue 1, pages 102-105
Published in print January 2005 | ISSN: 0305-7453
Published online January 2005 | e-ISSN: 1460-2091 | DOI:
Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay

Show Summary Details


Objectives: We have investigated the use of a viability dye, chloromethylfluorescein di-acetate (CMFDA), for antifungal susceptibility testing in a fluorescence microplate (FM) assay format.

Methods: For this FM assay, conidia were incubated in increasing concentrations of antifungal drug for 16 h and stained with CMFDA. Fluorescence, measured as mean fluorescence units (MFU) in a fluorescence microplate reader, was graphed relative to that of a drug-free control, and the MIC was defined as the lowest concentration of the drug that resulted in complete reduction (100%) in MFU for amphotericin B, or 90% reduction in MFU for itraconazole and voriconazole. Susceptibilities of 10 clinical isolates of Aspergillus fumigatus, Aspergillus terreus and Aspergillus niger to amphotericin B, itraconazole and voriconazole were tested in a blinded fashion using the FM and the NCCLS methods.

Results and conclusions: Reproducibility of the FM assay was excellent, and results correlated with those of the NCCLS microdilution method. The FM assay appears to be a rapid, objective method for testing fungal susceptibilities to itraconazole, voriconazole and amphotericin B.

Keywords: MICS; susceptibility testing; fluorescent dyes; Aspergillus spp.

Journal Article.  2280 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.